In May 2017, the Diabetes Technology Society convened a panel of US experts on inpatient
diabetes management to discuss the current and potential role of continuous subcutaneous …

Abstract Purpose of Review Summarize safety issues related to patients using insulin pump
therapy and continuous glucose monitoring systems (CGMS) in the outpatient setting when …

Objective This article aims to assess the reproducibility of Manufacturer and User Facility
Device Experience (MAUDE) data-driven studies by analyzing the data queries used in their …

Objective: To explore the clinical consequences and potential root causes of insulin pump-
associated adverse events (AEs) reported in the Food and Drug Administration's …

Background: Insulin pumps and continuous glucose monitoring (CGM) are commonly used
by patients with diabetes mellitus in the outpatient setting. The efficacy and safety of initiating …

Objective: To explore insulin pump-associated severe adverse events (SAEs) involving
intensive care unit (ICU) admissions and deaths and examine the impact of the COVID-19 …

Background Biotechnological syndromes refer to the illnesses that arise at the intersection of
human physiology and digital technology. Now that we experience health and illness …

The use of diabetes technology, including insulin pumps, continuous glucose monitoring
devices, and automated insulin delivery systems, has increased significantly in recent years …

The prevalence of diabetes has increased fourfold in the last three to four decades. It
currently affects more than 500 million people in the world. Of these, 90% of this is type 2 …

Continuous subcutaneous insulin infusion (CSII) therapy (also known as insulin pump
therapy) is employed to treat patients with diabetes mellitus. While most frequently seen in …